bpc-157 safety side effects Peptide bpc-157 safety side effects human

It remains classified as an investigational peptide rather than an approved medicine

Study BNT162-01 (Study 1) was a Phase 1/2, 2-part, dose-escalation trial that enrolled 60 participants, 18 through 55 years of age

BPC 157 has not been approved by FDA and should only be used in laboratory settings

10.1074/jbc.M111.253039 Summary Keywords stable gastric pentadecapeptide BPC 157, fistula, bleeding disorder, concept practical applicability, wound healing Citation Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB and Sikiric P (2021) Stable Gastric Pentadecapeptide BPC 157 and Wound Healing